Nuvation Bio Inc Stock Price, News & Analysis

Nuvation Bio (NYSE: NUVB), a global oncology company, announced its management team's participation in three upcoming investor conferences in September 2025. CEO David Hung, M.D. and CFO Philippe Sauvage will engage in fireside chats at the Cantor Global Healthcare Conference on September 4 and the H.C. Wainwright Global Investment Conference on September 9. The team will also conduct one-on-one meetings at the Citi BioPharma Back to School Conference on September 3.

Live webcasts of the fireside chats will be accessible through Nuvation Bio's Investor Relations website, with recordings available for 90 days after each event.

Nuvation Bio (NYSE: NUVB) reported significant milestones in Q2 2025, highlighted by the FDA approval of IBTROZI™ (taletrectinib) for advanced ROS1-positive non-small cell lung cancer on June 11, 2025. The company successfully initiated 70 patients on IBTROZI within seven weeks of approval, generating initial product revenue of $1.2 million in just 13 business days.

Financial highlights include a strong balance sheet with $607.7 million in cash and equivalents, and secured $200 million in non-dilutive financing from Sagard Healthcare Partners. The company reported a net loss of $59.0 million ($0.17 per share) for Q2 2025, with research and development expenses of $27.4 million and selling, general, and administrative expenses of $38.5 million.

Nuvation Bio (NYSE:NUVB) announced upcoming presentations of new data for its FDA-approved drug IBTROZI™ (taletrectinib) at two major conferences: the IASLC 2025 World Conference on Lung Cancer (WCLC) and the European Society of Medical Oncology Congress Meeting (ESMO).

The presentations will showcase updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI's efficacy and safety in treating adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The data will be presented across multiple sessions at WCLC (September 6-9, 2025, Barcelona) and ESMO (October 17-21, 2025, Berlin).

Additionally, Nuvation Bio will sponsor a satellite symposium at WCLC titled "Under the Microscope: Focusing on ROS1+ NSCLC" featuring presentations from leading oncology experts.

Nuvation Bio (NYSE: NUVB), a global oncology company, will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its second quarter 2025 financial results and provide business updates.

Interested participants can access the live conference call by dialing +1 833-470-1428 (U.S. toll-free) with access code 926066. A webcast will be available through the Investor Relations section of Nuvation Bio's website, with a recording accessible for 90 days after the event.

Nuvation Bio (NYSE:NUVB) announced that its drug taletrectinib (IBTROZI™) has been added as a Preferred Agent in the National Comprehensive Cancer Network® Clinical Practice Guidelines for Non-Small Cell Lung Cancers. The drug, which received FDA approval on June 11, is specifically recommended for ROS1-positive NSCLC patients across all treatment lines.

IBTROZI is designed as a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor targeting a rare form of lung cancer that affects approximately 2% of NSCLC cases, representing about 3,000 new diagnoses annually in the U.S. The guidelines particularly recognize the drug's benefits for patients with brain metastases and those with acquired resistance after first-line therapy.

The FDA has approved Nuvation Bio's IBTROZI (taletrectinib) for treating adult patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). IBTROZI, a next-generation oral ROS1 tyrosine kinase inhibitor, demonstrated impressive efficacy in the TRUST clinical trials with confirmed overall response rates of 90% and 85% in TKI-naïve patients in TRUST-I and TRUST-II respectively. The drug showed strong brain-penetrant efficacy with intracranial response rates of 73% in TKI-naive patients and 63% in TKI-pretreated patients. The safety profile was favorable, with most adverse events being low grade and manageable. ROS1+ NSCLC affects approximately 3,000 new patients annually in the U.S., primarily younger individuals around age 50. The approval follows Priority Review and is supported by one of the largest clinical trial programs in ROS1+ NSCLC, involving over 300 patients.

Nuvation Bio (NYSE: NUVB) will present new data from its pivotal Phase 2 clinical studies TRUST-I and TRUST-II at the ASCO 2025 Annual Meeting (May 30-June 3, 2025). The presentation will showcase the efficacy and safety results of taletrectinib, their next-generation oral tyrosine kinase inhibitor for treating advanced ROS1-positive non-small cell lung cancer (NSCLC). The drug is currently under Priority Review by the FDA with a PDUFA date of June 23, 2025. Dr. Maurice Perol from Léon Bérard Cancer Center will present findings demonstrating comparable results across different ethnicities and world regions. The presentation is scheduled for May 31, 2025, at 1:30-4:30 p.m. CT.

Nuvation Bio (NYSE: NUVB) has announced that it will present new comparative data for its drug taletrectinib versus entrectinib in treating ROS1-positive non-small cell lung cancer (NSCLC) at the upcoming ISPOR 2025 conference. The presentation will feature a matching-adjusted indirect comparison (MAIC) study between the two treatments.

The poster presentation will be delivered by Dr. Misako Nagasaka from UCI School of Medicine on May 14, 2025, during the 10:30 a.m. - 1:30 p.m. ET session at ISPOR 2025 in Montreal. The presentation materials will be made available on Nuvation Bio's website following the event.

Nuvation Bio (NYSE: NUVB), a global oncology company, announced its leadership team's participation in three upcoming investor conferences in May 2025. David Hung, M.D., Founder, President, and CEO, along with Philippe Sauvage, CFO, will engage in fireside chats at:

• H.C. Wainwright BioConnect Conference (May 20, 3:00 PM ET)
• RBC Capital Markets Healthcare Conference (May 21, 1:35 PM ET)
• TD Cowen Oncology Innovation Summit (May 28, 3:30 PM ET, virtual)

Live webcasts will be available on Nuvation Bio's investor website, with recordings accessible for 90 days after each event.